BIIB - Biogen Inc Stock Price, Fair Value and News

220.30USD+0.58 (+0.26%)Delayed as of 09 May 2024, 11:59 am ET

Market Summary

USD220.30+0.58

Delayedas of 09 May 2024, 11:59 am

0.26%

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

32.0B

Price/Earnings (Trailing)

27.42

Price/Sales (Trailing)

3.31

EV/EBITDA

17.66

Price/Free Cashflow

23.03

BIIB Price/Sales (Trailing)

BIIB Profitability

Operating Margin

94.35%

EBT Margin

13.42%

Return on Equity

7.67%

Return on Assets

4.39%

Free Cashflow Yield

4.34%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

9.7B

Rev. Growth (Yr)

-7%

Rev. Growth (Qtr)

-4.01%

BIIB Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

1.42%

Earnings Growth (Qtr)

57.55%

Breaking Down BIIB Revenue

52 Week Range

219.00319.76

(Low)(High)

Last 7 days

1.7%

Last 30 days

7.2%

Last 90 days

-8.6%

Trailing 12 Months

-30.0%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

2.1

Debt/Equity

0.41

Debt/Cashflow

0.26

BIIB Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

8.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.7B	0	0	0
2023	10.1B	10.0B	10.0B	9.8B
2022	10.8B	10.6B	10.4B	10.2B
2021	12.6B	11.7B	11.1B	11.0B
2020	14.4B	14.5B	14.3B	13.4B
2019	13.8B	14.1B	14.2B	14.4B
2018	12.6B	12.9B	13.2B	13.5B
2017	11.5B	11.7B	11.8B	12.3B
2016	10.9B	11.2B	11.4B	11.4B
2015	10.1B	10.3B	10.6B	10.8B
2014	7.6B	8.3B	9.0B	9.7B
2013	5.6B	5.9B	6.4B	6.9B
2012	5.1B	5.3B	5.4B	5.5B
2011	4.8B	4.8B	4.9B	5.0B
2010	4.4B	4.6B	4.6B	4.7B
2009	4.2B	4.3B	4.3B	4.4B
2008	0	3.5B	3.8B	4.1B
2007	0	0	0	3.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Biogen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	keeney adam	sold (taxes)	-59,651	216	-276	head of corporate development
May 01, 2024	keeney adam	acquired	-	-	938	head of corporate development
Apr 02, 2024	singhal priya	sold	-19,817	213	-93.00	head of development
Apr 01, 2024	murphy nicole	acquired	-	-	240	head of pharm ops and tech
Apr 01, 2024	murphy nicole	sold (taxes)	-25,135	214	-117	head of pharm ops and tech
Feb 22, 2024	singhal priya	sold	-57,962	221	-262	head of development
Feb 16, 2024	gregory ginger	acquired	-	-	4,704	evp, human resources
Feb 16, 2024	alexander susan h	acquired	-	-	5,037	evp chief legal officer
Feb 16, 2024	murphy nicole	sold (taxes)	-133,639	219	-610	head of pharm ops and tech
Feb 16, 2024	izzar rachid	acquired	-	-	2,017	head of global product strat.

Which funds bought or sold BIIB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	MONTAG A & ASSOCIATES INC	unchanged	-	-9,016	45,067	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	209	32,150,600	52,487,400	0.01%
May 07, 2024	O'Dell Group, LLC	sold off	-100	-16,562	-	-%
May 07, 2024	Concurrent Investment Advisors, LLC	added	109	276,202	646,244	0.03%
May 07, 2024	M&T Bank Corp	reduced	-2.35	-816,921	3,573,250	0.01%
May 07, 2024	KCM INVESTMENT ADVISORS LLC	added	1.65	-114,972	636,755	0.02%
May 07, 2024	Washington Trust Advisors, Inc.	added	9.3	-1,985	20,270	-%
May 07, 2024	WestEnd Advisors, LLC	unchanged	-	-87.00	431	-%
May 07, 2024	Israel Discount Bank of New York	reduced	-23.66	-200,178	349,967	0.44%
May 07, 2024	Bank Pictet & Cie (Europe) AG	added	6.72	-68,647	551,366	0.01%

Are Funds Buying or Selling BIIB?

Are funds buying BIIB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIIB

No. of Funds

Unveiling Biogen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	primecap management co/ca/	11.22%	16,264,481	SC 13G/A
Feb 12, 2024	vanguard group inc	10.02%	14,521,342	SC 13G/A
Feb 12, 2024	vanguard group inc	9.94%	14,406,879	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	14,246,320	SC 13G/A
Feb 09, 2023	primecap management co/ca/	10.9%	15,700,576	SC 13G/A
Feb 09, 2023	vanguard group inc	8.32%	11,976,623	SC 13G/A
Jan 24, 2023	blackrock inc.	9.9%	14,260,137	SC 13G/A
Mar 07, 2022	blackrock inc.	9.4%	13,736,954	SC 13G/A
Feb 10, 2022	primecap management co/ca/	10.73%	15,757,405	SC 13G/A
Feb 09, 2022	vanguard group inc	7.85%	11,537,299	SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 24, 2024	10-Q	Quarterly Report
Apr 24, 2024	8-K	Current Report
Apr 12, 2024	PRE 14A	PRE 14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Biogen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	358.5B	85.6B	-1.74%	-7.51%	9.32	4.19	5.68%	202.39%
MRK	328.0B	61.4B	2.34%	10.30%	142.26	5.34	6.11%	-82.30%
AMGN	164.9B	29.5B	14.19%	31.13%	43.82	5.58	12.76%	-52.47%
PFE	160.3B	57.8B	6.40%	-25.71%	127.84	2.77	76.51%	-86.81%
GILD	80.9B	27.4B	-6.51%	-17.64%	166.89	2.95	1.51%	-91.32%
TEVA	17.8B	16.0B	10.77%	72.86%	-36.05	1.11	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-2.02%	-10.81%	-550.77	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-7.02%	-22.02%	9.39	2.36	54.01%	364.56%
BHC	2.6B	9.0B	-27.55%	19.80%	-5.67	0.29	10.01%	-27.45%
AMPH	2.0B	644.4M	2.87%	15.89%	14.76	3.15	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-25.10%	-28.68%	-4.27	2.02	24.65%	80.36%
TXMD	23.3M	1.3M	-6.48%	-47.40%	-2.27	17.89	-98.14%	-109.18%
ACRX	17.5M	-	-11.21%	50.12%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	5.13%	-93.31%	-0.19	0.14	80.00%	43.08%
ACOR	968.8K	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Biogen Inc News

Latest updates

Biogen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.0%	2,291	2,386	2,530	2,456	2,463	2,544	2,509	2,589	2,532	2,734	2,779	2,775	2,694	2,853	3,376	3,682	3,534	3,671	3,600	3,617	3,490
Costs and Expenses	-12.8%	1,826	2,095	2,672	1,748	2,025	1,940	1,137	1,320	2,184	2,582	2,488	2,193	1,720	2,686	2,290	1,707	1,714	1,894	1,794	1,661	1,987
S&GA Expenses	-4.4%	582	609	788	548	605	633	563	573	635	788	654	637	595	806	573	555	570	665	555	588	568
EBITDA Margin	3.9%	0.22*	0.21*	0.23*	0.38*	0.44*	0.43*	0.40*	0.29*	0.22*	0.23*	0.21*	0.26*	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.2%	69.00	72.00	64.00	49.00	63.00	55.00	60.00	66.00	66.00	66.00	66.00	56.00	65.00	56.00	56.00	66.00	44.00	46.00	46.00	48.00	48.00
Income Taxes	67.2%	71.00	43.00	-72.90	115	51.00	54.00	236	217	126	443	-25.90	-409	44.00	13.00	241	446	292	276	211	248	423
Earnings Before Taxes	59.4%	465	292	-141	708	438	604	1,371	1,270	347	405	291	582	467	353	958	2,038	1,699	1,728	1,779	1,759	1,860
EBT Margin	1.8%	0.13*	0.13*	0.16*	0.31*	0.36*	0.35*	0.33*	0.22*	0.15*	0.16*	0.15*	0.20*	-	-	-	-	-	-	-	-	-
Net Income	57.5%	393	250	-68.10	592	388	550	1,135	1,058	304	368	329	449	410	358	702	1,542	1,399	1,440	1,546	1,494	1,409
Net Income Margin	2.3%	0.12*	0.12*	0.15*	0.27*	0.31*	0.30*	0.28*	0.19*	0.13*	0.14*	0.14*	0.16*	-	-	-	-	-	-	-	-	-
Free Cashflow	1062.6%	507	-52.70	518	416	389	-261	602	700	104	787	763	1,155	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.0%	26,568	26,845	28,193	25,157	24,598	24,554	24,854	25,081	23,614	23,877	23,807	24,470	23,855	24,619	24,934	25,512	26,119	27,234	27,484	26,288	26,446
Current Assets	-1.5%	6,756	6,859	8,454	10,432	9,763	9,791	9,766	9,741	7,916	7,857	7,162	7,184	6,720	6,887	7,843	8,494	8,007	8,382	8,448	7,910	8,943
Cash Equivalents	2.3%	1,074	1,050	2,288	2,618	2,898	3,419	3,676	2,647	1,749	2,261	1,542	1,742	1,218	1,331	2,225	2,385	2,591	2,914	2,344	1,723	2,243
Inventory	-0.4%	2,517	2,527	2,982	1,334	1,281	1,344	1,375	1,294	1,215	1,352	1,348	1,255	1,172	1,069	1,028	953	859	804	752	777	770
Net PPE	-1.0%	3,275	3,310	3,302	3,307	3,301	3,299	3,266	3,355	3,373	3,416	3,411	3,442	3,438	3,412	3,360	3,331	3,282	3,247	3,138	3,078	3,014
Goodwill	0.1%	6,227	6,219	474	5,754	5,752	5,749	5,741	5,750	5,758	5,761	5,761	5,764	5,763	5,762	5,756	5,751	5,752	5,758	5,746	5,749	5,640
Liabilities	-5.7%	11,355	12,045	13,714	10,696	10,811	11,166	12,087	13,218	12,394	12,918	12,925	13,256	13,192	13,933	14,190	14,223	13,582	13,895	13,492	13,339	12,624
Current Liabilities	-6.2%	3,223	3,434	5,022	3,187	3,015	3,273	3,926	5,018	3,947	4,298	4,212	3,347	3,166	3,742	3,804	3,447	4,639	4,864	4,432	3,211	3,149
Long Term Debt	-7.3%	6,290	6,788	6,786	6,285	6,283	6,281	6,279	6,277	6,276	6,274	6,272	7,269	7,267	7,426	7,425	7,424	4,460	4,459	4,458	5,949	5,943
Shareholder's Equity	2.8%	15,213	14,799	14,484	14,461	13,787	13,388	12,767	11,863	11,221	10,960	10,882	11,215	10,663	10,686	10,745	11,289	12,537	13,339	13,992	12,949	13,822
Retained Earnings	2.2%	18,021	17,628	17,378	17,446	16,854	16,467	15,916	14,960	14,216	13,912	13,544	13,901	13,834	13,976	13,961	14,467	15,673	16,455	17,065	16,183	17,027
Additional Paid-In Capital	8.9%	330	303	242	171	91.00	73.00	-	-	119	68.00	-	-	-	-	-	-	0.00	-	-	-	-
Shares Outstanding	0.2%	145	145	145	145	144	144	146	146	147	147	148	150	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-4.10	-6.40	-9.60	-9.50	-8.70	-9.10	-21.60	64.00	452	463	-19.00	-14.20	-14.00	-19.50	-10.00	-4.10	-4.10	-4.10	-7.90
Float	-	-	-	-	41,191	-	-	-	29,398	-	-	-	51,265	-	-	-	42,103	-	-	-	43,010	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	4325.6%	553	13.00	592	487	455	-175	661	737	162	838	805	1,227	769	-367	1,181	1,949	1,467	1,960	1,695	1,964	1,460
Share Based Compensation	-61.9%	73.00	191	-64.80	-74.10	76.00	189	-65.70	-58.00	68.00	170	-57.60	-55.80	70.00	132	-35.40	-49.50	68.00	139	-47.80	-55.00	46.00
Cashflow From Investing	89.9%	-66.00	-652	-1,742	-753	-953	-141	1,672	694	-648	-112	-233	-152	-64.70	-166	-52.40	-832	443	708	-365	-110	239
Cashflow From Financing	32.0%	-439	-646	849	-9.80	-43.40	-7.40	-1,251	-471	-16.50	10.00	-746	-564	-785	-401	-1,312	-1,313	-2,245	-2,116	-689	-2,375	-679
Buy Backs	-	-	-	-	-	-	-	250	500	-	-	750	450	600	400	1,250	2,809	2,220	2,093	718	2,402	656

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIIB Income Statement

2024-03-31

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 2,290.5	$ 2,463.0
Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets	542.2	662.8
Research and development	452.9	570.6
Selling, general and administrative	581.5	605.0
Amortization and impairment of acquired intangible assets	78.3	50.2
Collaboration profit sharing/(loss reimbursement)	65.6	57.1
Restructuring charges	11.5	9.6
Other (income) expense, net	93.7	69.4
Total cost and expense	1,825.7	2,024.7
Income before income tax (benefit) expense	464.8	438.3
Income tax (benefit) expense	71.4	50.7
Net income	393.4	387.6
Net income (loss) attributable to noncontrolling interests, net of tax	0.0	(0.3)
Net income attributable to Biogen Inc.	$ 393.4	$ 387.9
Net income per share:
Basic earnings per share attributable to Biogen Inc.	$ 2.71	$ 2.69
Diluted earnings per share attributable to Biogen Inc.	$ 2.70	$ 2.67
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.	145.2	144.4
Diluted earnings per share attributable to Biogen Inc.	145.9	145.2
Product, net
Total revenue	$ 1,711.9	$ 1,763.3
Revenue from anti-CD20 therapeutic programs
Total revenue	394.0	399.5
Contract manufacturing, royalty and other revenue
Total revenue	$ 184.6	$ 300.2

BIIB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,074.4	$ 1,049.9
Inventory	2,516.8	2,527.4
Other current assets	1,165.3	1,182.0
Total current assets	6,756.2	6,859.3
Property, plant and equipment, net	3,275.3	3,309.7
Operating lease assets	428.1	420.0
Intangible assets, net	8,284.7	8,363.0
Goodwill	6,227.4	6,219.2
Deferred tax asset	898.3	928.6
Investments and other assets	697.6	745.0
Total assets	26,567.6	26,844.8
Current liabilities:
Current portion of term loan	250.0	150.0
Taxes payable	231.2	257.4
Accounts payable	387.0	403.3
Accrued expense and other	2,354.6	2,623.6
Total current liabilities	3,222.8	3,434.3
Notes payable and term loan	6,290.1	6,788.2
Deferred tax liability	658.1	641.8
Long-term operating lease liabilities	406.5	400.0
Other long-term liabilities	777.1	781.1
Total liabilities	11,354.6	12,045.4
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:
Preferred stock, par value $0.000 per share	0.0	0.0
Common stock, par value $— per share	0.1	0.1
Additional paid-in capital	329.5	302.5
Accumulated other comprehensive income (loss)	(160.5)	(153.7)
Retained earnings	18,021.0	17,627.6
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total equity	15,213.0	14,799.4
Total liabilities and equity	26,567.6	26,844.8
Nonrelated Party
Current assets:
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively	1,604.5	1,664.1
Related Party
Current assets:
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively	$ 395.2	$ 435.9

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Christopher A. Viehbacher
WEBSITE	biogen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	8725

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Wed May 08 2024, market cap of Biogen Inc is 31.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BIIB's PE ratio (Price to Earnings) is 27.42 and Price to Sales (PS) ratio is 3.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.018 (multiply by 100 for percentage) rate of return.